AI and Human Brains: A New Alliance Against Parkinson's Disease

NEW HAVEN, Conn. – January 28, 2026 – A groundbreaking initiative is underway to bridge a critical gap in Parkinson’s disease research, powered by a unique fusion of artificial intelligence and experiments conducted on whole, non-living human brains. Bexorg, Inc., a New Haven-based biotechnology firm, announced today it has received a significant research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The funding is aimed at a singular, vital goal: identifying reliable biological markers for a promising therapeutic target known as TRPML1.

The collaboration represents a bold step toward overcoming one of the most formidable obstacles in developing disease-modifying treatments for neurodegenerative conditions. By leveraging its unprecedented technology platform, Bexorg aims to create a roadmap that could accelerate not just its own programs, but the entire field’s quest for a cure for Parkinson’s.

Bridging the Translational Gap in Drug Discovery

For decades, the path to developing new drugs for central nervous system (CNS) disorders has been fraught with failure. Industry reports consistently show that over 95% of CNS drug candidates that enter clinical trials fail to reach patients. A primary reason for this staggering attrition rate is the so-called “translational gap”—the chasm between promising results in laboratory models, like cells in a petri dish or animal studies, and actual effectiveness in the complex human brain.

This is the precise challenge the new grant seeks to address. MJFF has identified TRPML1 as a compelling target for new Parkinson's therapies, but a lack of “translational biomarkers” has stalled progress. These biomarkers are measurable indicators that would allow scientists to confirm, in human clinical trials, that a drug is successfully engaging with its intended target. Without them, it is nearly impossible to know if a drug is working as designed.

“Through this grant, MJFF is supporting Bexorg to leverage its postmortem whole-human brain platform in advancing TRPML1 research to bridge the translational gap between preclinical drug discovery and advancement of therapies in clinical trials,” said Paul Wes, Ph.D., Vice President of Drug Discovery at Bexorg. “With multiple biotechnology and pharmaceutical companies pursuing TRPML1-targeted programs, our collaboration with MJFF aims to accelerate the entire field toward developing disease-modifying therapies for people living with Parkinson’s disease.”

This sentiment is echoed by the foundation, which launched its Targets to Therapies Initiative in 2024 to de-risk promising avenues for treatment. “Validating TRPML1 will close important translational gaps and inform multiple therapeutic programs,” said Shalini Padmanabhan, Ph.D., Senior Vice President of Translational Research at MJFF. “Bexorg’s capabilities will help advance this work and may also inform future efforts to evaluate additional targets for Parkinson’s therapies.”

A New Frontier: The Human Brain as a Laboratory

At the heart of this effort is Bexorg's proprietary BrainEx platform, a technology that sounds like science fiction but is grounded in years of pioneering research at Yale University. Founded in 2021 by Dr. Zvonimir Vrselja and Dr. Nenad Sestan, the company has developed a method to study donated postmortem human brains in a way never before possible.

The system works by perfusing the brain’s vascular network with a specially designed fluid that mimics blood, restoring oxygen and nutrients. This process revives critical cellular and metabolic functions within the intact organ, allowing researchers to observe the intricate biological machinery of the human brain in action. Crucially, the technology does not restore any level of consciousness or higher-level brain function, a key ethical boundary.

This platform allows scientists to administer drug compounds and measure their effects in real-time, providing an unparalleled view of how a potential therapy behaves in the actual human organ it is designed to treat. The vast amounts of molecular data generated from these experiments—spanning genomics, proteomics, and metabolomics—are then fed into advanced AI models. These algorithms are trained to detect subtle patterns, identify novel drug targets, and, in the case of the MJFF grant, discover the specific biomarkers that signal a drug’s activity at TRPML1.

This human-first approach is a radical departure from traditional methods. By moving away from animal models that often fail to replicate human neurodegenerative diseases, Bexorg aims to generate data that is far more predictive of clinical success, potentially saving billions of dollars and years of wasted effort in failed trials.

The Promise and Science of TRPML1

The focus of the grant, TRPML1, is a protein that acts as an ion channel on the surface of lysosomes—the cell's waste disposal and recycling centers. In a healthy brain, lysosomes play a vital role in breaking down and clearing out damaged proteins and other cellular debris through a process called autophagy.

In Parkinson’s disease, this system is often impaired. Misfolded alpha-synuclein proteins accumulate into toxic clumps, called Lewy bodies, which damage and kill dopamine-producing neurons, leading to the characteristic motor symptoms of the disease. Scientific evidence suggests that activating the TRPML1 channel can reinvigorate the lysosomal system, enhancing its ability to clear these toxic protein aggregates.

By boosting this natural cellular cleanup process, TRPML1-targeted drugs hold the potential to do more than just manage symptoms—they could slow or even halt the progression of the disease itself. However, proving this in a clinical trial requires a biomarker. Researchers need a way to measure whether a drug is successfully activating TRPML1 in a patient's brain and kickstarting the desired autophagic process. The discoveries made through Bexorg's platform could provide the tools to do just that.

The Ethical Imperative of Innovation

Conducting research on whole human brains carries a profound ethical responsibility, a fact Bexorg and its partners have placed at the forefront of their operations. The brains used for this research are sourced through organizations like LifeNet Health, a federally designated organ procurement organization that works with donors and their families to facilitate the gift of tissue for medical research.

This process is governed by rigorous ethical standards, including the Uniform Anatomical Gift Act, and requires full, informed consent. Bexorg also operates under the guidance of an independent board of bioethics experts to ensure its work remains within strict legal and ethical boundaries. The distinction that consciousness is not restored is paramount, ensuring that the research honors the donor's gift by advancing science without crossing fundamental ethical lines.

This framework allows the final act of an individual's life to become a source of hope for millions. The data generated from each donated brain contributes to one of the world's largest repositories of human CNS data, a resource that will continue to fuel discoveries for neurodegenerative conditions like Alzheimer's and Parkinson's for years to come. The collaboration between Bexorg and MJFF is not just about a single target or a single drug; it's about building a new, more reliable and human-centric paradigm for discovering the cures of tomorrow.